WIL 1902
Alternative Names: WIL-1902Latest Information Update: 28 Sep 2023
At a glance
- Originator Whanin Pharmaceutical
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Parkinson's-disease in South Korea (Parenteral, Injection)
- 20 Nov 2019 WIL 1902 is available for licensing as of 20 Nov 2019. https://www.whanin.com/
- 01 Aug 2019 Early research in Parkinson's disease in South Korea (Parenteral) before November 2019 (Whanin Pharmaceuticals pipeline)